AstraZeneca plc vs McCormick & Company, Incorporated — how do they compare? AstraZeneca plc trades at $158.42 (market cap $248.14B), while McCormick & Company, Incorporated trades at $52.75 (market cap $14.22B). The key difference: AstraZeneca plc is far larger — about 17.5× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| AZN | MKC | |
|---|---|---|
Market Cap | $248.14B | $14.22B |
Sector | Health | Consumer Staples |
52-Week High | $209.48 | $72.26 |
52-Week Low | $147.06 | $45.60 |
Enterprise Value | $275.41B | $18.82B |
Dividend Yield | 2.01% | 3.63% |
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →